



PRESS RELEASE

FOR IMMEDIATE RELEASE

August 11, 2009

Indel Therapeutics Awarded Key Platform Patent for Novel Antimicrobial Drug Discovery Platform Technology

Vancouver, BC – Indel Therapeutics Inc., a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance, announced today the issuance of a key platform patent by the U.S. Patent and Trademark Office for its antimicrobial drug discovery technology. This broad platform patent is for the diagnosis and treatment of infectious diseases through indel-differentiated proteins.

“The issuance of this patent is a big milestone for the Company and further protects its novel antimicrobial drug discovery technology,” said Malcolm Kendall, the Chief Executive Officer of Indel Therapeutics. “The breadth of this patent is impressive, providing both diagnostic and therapeutic applications of our technology across the discovery of drugs for bacterial, fungal, parasitic and viral infections.”

Indel’s core technology is based on an unexploited and novel antimicrobial targeting paradigm. The Indel platform identifies and targets discrete amino acid insertion or deletion differences (“indels”) between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans. Based upon these structural differences, the Company can selectively target the pathogen protein with small molecules without binding to the human counterpart, thereby potentially reducing toxicity and microbial resistance. The patented indel technology opens a rich, new area for developing novel antimicrobials for the treatment of bacterial and parasitic infections and potentially fungal and viral infections.

About Indel Therapeutics

Indel Therapeutics Inc. is a Vancouver-based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases and has the potential to provide an advantage against drug resistance. For more information, please visit www.indelrx.com.

Indel Therapeutics Contact:

Malcolm Kendall, CEO

T: (604) 551-8464

mkendall@indelrx.com